3/5
08:08 am
mrkr
Marker Therapeutics, Inc. (NASDAQ: MRKR) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $8.00 price target on the stock.
High
Report
Marker Therapeutics, Inc. (NASDAQ: MRKR) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $8.00 price target on the stock.
2/25
08:04 am
mrkr
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference [Yahoo! Finance]
Medium
Report
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference [Yahoo! Finance]
2/25
07:00 am
mrkr
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
Medium
Report
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
2/12
07:46 am
mrkr
Marker Therapeutics, Inc. (NASDAQ: MRKR) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Low
Report
Marker Therapeutics, Inc. (NASDAQ: MRKR) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
12/19
08:15 am
mrkr
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma [Yahoo! Finance]
Medium
Report
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma [Yahoo! Finance]
12/19
08:11 am
mrkr
Marker Therapeutics Announces $16.1 Million Private Placement [Yahoo! Finance]
Medium
Report
Marker Therapeutics Announces $16.1 Million Private Placement [Yahoo! Finance]
12/19
08:06 am
mrkr
Marker Therapeutics Announces $16.1 Million Private Placement
Medium
Report
Marker Therapeutics Announces $16.1 Million Private Placement
12/19
08:05 am
mrkr
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma
Medium
Report
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma
12/17
07:32 am
mrkr
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer [Yahoo! Finance]
Medium
Report
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer [Yahoo! Finance]
12/17
07:00 am
mrkr
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer
Low
Report
Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer